Incidence and prognosis factors of extragonadal choriocarcinoma in males: a population-based study

Jingping Qiu¹Shi Jia²Guang Li¹

¹Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China; ²7th General Surgery Unit, Shengjing Hospital of China Medical University, Shenyang, China

Background: Choriocarcinoma usually occurs in females and sometimes occurs in the testicles of males. Extragenadal choriocarcinoma in males was previously described in case reports, and our understanding of this type of cancer has remained limited. The purpose of this study was to explore the incidence, treatment and prognostic factors of extragonadal choriocarcinoma in males.

Materials and methods: Two cohorts were identified from the Surveillance, Epidemiology, and End Results (SEER) Program by histology, tumor site and sex. One cohort of 115 patients was created using the SEER nine registries (1973–2014) to estimate the incidence. The other cohort of 197 patients was created using the SEER 18 registries (1973–2013) to estimate the patient demographics and survival.

Results: The median age at diagnosis was 30 years. The most common primary tumor location was the mediastinum followed by the retroperitoneum and the brain. Approximately 23% of patients underwent beam radiation therapy, whereas 63.5% underwent surgery. The estimated one- and 5-year cause-specific survival rates were 49% and 35%, respectively. The multivariate analysis showed that the age at diagnosis, ie, a younger age of 0–19 years old, and the primary tumor site, ie, the brain, were the independent prognostic factors and were correlated with a favorable prognosis. The median survival time of patients was 186 months, 13 months and 4 months in the 0–19, 20–49 and 50+ years of age, respectively.

Conclusion: Extragenadal choriocarcinoma in males is a rare malignancy with a poor prognosis. A young age at diagnosis and primary tumor site in the brain were the independent prognostic factors.

Keywords: choriocarcinoma, incidence, beam radiation, surgery, prognosis

Introduction

Choriocarcinoma is a highly malignant neoplasm that most commonly occurs in females and is related to a gestational event. In males, choriocarcinoma is generally considered a nonseminomatous germ cell tumor, which represents less than 5% of all germ cell tumors in males.¹ Choriocarcinoma in males commonly develops in the gonads (ie, testes). In some cases, extragonadal choriocarcinoma occurs in midline locations, such as the mediastinum, retroperitoneum and pineal gland, with rare cases reported in the parenchymal organs, such as the lungs, gastrointestinal tract and breast.^{2–7} Although the burden of extragonadal germ cell tumors has been previously described in population-based studies, extragonadal choriocarcinoma in males has not been specified.^{8,9}

Several hypotheses have been proposed by pathologists to explain the etiology of extragonadal choriocarcinoma: 1) the tumor arises from retained primordial

Correspondence: Guang Li
Department of Radiation Oncology,
The First Hospital of China Medical
University, 155 Nanjing North Street,
Shenyang, China
Tel +86 024 8328 2137
Email 13804058616@163.com

germ cells that migrate abnormally during embryogenesis; 2) metastasis occurs from a gonadal choriocarcinoma that regressed spontaneously; and 3) development is a consequence of multidirectional tumor differentiation from a common stem cell in malignant epithelium. Recently, novel somatic and germline mutations have been reported to correlate with extragonadal germ cell tumors; however, strict pathological distinctions for the development of choriocarcinoma seem to be very difficult for pathologists to apply.^{10–12} The etiology suggests that prognostic factors of extragonadal choriocarcinoma should not be implied from the extragonadal germ cell cancer or testicular choriocarcinoma, despite the 5-year relative survival rate of 71% and 68% for extragonadal germ cell cancer in Europe and in the USA, respectively, and the testicular choriocarcinoma 5-year survival rate of less than 80% in the USA.^{9,13,14} Based on previous case reports, the prognostic factors of extragonadal choriocarcinoma in males was not fully understood.

The Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute provides data on cancers in 18 geographical areas of the USA and covers ~26% of the population. We performed this population-based study to explore the incidence and prognostic factors of extragonadal choriocarcinoma in males and aimed to provide a more accurate estimate of the incidence and survival rate of this very rare disease.

Materials and methods

The SEER Program

Two cohorts of patients were created using the SEER program (www.seer.cancer.gov) SEER*Stat Database. One cohort to estimate the incidence was created using the SEER 9 Registries Research Data, November 2016 Submission (1973–2014)<Katrina/Rita Population Adjustment>. The other cohort to estimate the patient demographics and survival was created using SEER 18 Registries Research Data+Hurricane Katrina Impacted Louisiana Cases, November 2015 Submission (1973–2013 varying).

The selection of patients was based on 1) ICD for Oncology (ICD-O) codes of 9100/2: Choriocarcinoma in situ, NOS, 9100/3: Choriocarcinoma, NOS, 9101/2: Choriocarcinoma combined with other germ cell elements, in situ, 9101/3: Choriocarcinoma combined with other germ cell elements; 2) sex is male; 3) site is not “Testis – male”. Finally, one cohort of 115 eligible patients was enrolled to estimate the incidence and the other cohort of 197 eligible

patients was enrolled to estimate the patient demographics and survival in this study.

Statistical analysis

Incidence rates were analyzed with SEER*Stat Software version 8.3.5 (Surveillance Research Program, National Cancer Institute, seer.cancer.gov/seerstat). Trends in incidence rates were analyzed with the Joinpoint Regression Program (version 4.5.0.1; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute) using the Joinpoint regression model and permutation tests for identifying changes in trends.¹⁵ Statistical analysis was performed with SPSS Statistical Package version 24.0 (SPSS Inc, Chicago, IL, USA). Rates were per 100,000 and age was adjusted to the 2000 US standard population. Percent change was calculated using 1 year for each end point. The tumor stage was classified by SEER summary stage 1977 (1995–2000). Marital status was divided into two groups: married and others, which included never married, widowed, divorced, separated, unmarried or domestic partner, and unknown. The age at diagnosis between two groups was compared using a *t*-test. Rates of surgery and beam radiation treatment between groups were compared using chi-squared test. The 1-, 3- and 5-year cause-specific survival (CSS) rates were estimated by the life table method, and median survival rates were estimated by Kaplan–Meier analyses and then compared statistically using the log-rank test. The prognostic factors were determined by univariate regression analysis, where HRs with 95% CIs were calculated to estimate the risk of death. A multivariable analysis was further performed to find independent prognostic factors using the Cox proportional hazards. $P < 0.05$ was considered statistically significant.

Ethical approval

The ethical approval and informed consent statements are not applicable for this type of research. The data accessed from the SEER database are freely available.

Results

Incidence

Between 1973 and 2014, a total of 115 male patients exhibiting extragonadal choriocarcinoma were identified in the SEER nine registries. The overall incidence rate for extragonadal choriocarcinoma in males during that period based on the SEER data was 0.022 per 100,000 people

(95% CI: 0.018 to 0.026). In 1977 and 2014, the frequency was zero, which cannot be processed by Joinpoint trend analysis; therefore, we calculated the age-adjusted rates from 1978 to 2013 instead. The incidence of extragonadal choriocarcinoma in males changed from 0.0072 per 100,000 people in 1978 to 0.0430 in 1981, with an annual percent change (APC) of 23.23 and then dropped to 0.0272 in 2013 with an APC of -3.09 (95% CI= -4.9 to -1.3 , $P<0.05$), demonstrating no significant change from 1981 to 2013 (Figure 1).

Patient demographics

From 1973 to 2013, 197 cases of extragonadal choriocarcinoma in males were identified in the SEER database. Patient demographics and clinical characteristics of the study population are summarized in Table 1. The median age of diagnosis was 30 years with a range of 0–84 years and percentile of 21–46 years. The most common primary tumor location was the mediastinum, with 44.8% of cases occurring in this location ($n=30$), followed by the retroperitoneum and the brain. Other tumor sites included the liver ($n=2$), intrahepatic bile duct ($n=1$), nasal cavity ($n=1$), subcutaneous connective tissue ($n=2$), adrenal gland ($n=1$) and abdomen ($n=1$).

Treatment

The ratio of patients who received beam radiation therapy was 22.8% for the whole cohort but was lower in older patients and European-Americans, and the ratio receiving surgery was 63.5% overall, which has decreased over the last decades. Among the tumors located at different sites, brain tumor patients were more prone to receive beam radiation, and mediastinum tumor patients were less likely to receive surgery. The treatment characteristics of the cohort are shown in Table 2.

Survival

The median follow-up time was 9 months (with a range of 0–427 months). The median survival time of the cohort was 11 months (95% CI: 5.7 to 16.3 months), whereas the estimated 1-, 3- and 5-year overall survival rates were 46%, 33% and 31%, respectively. The estimated 1-, 3- and 5-year CSS rates were 49%, 37% and 35%, respectively.

The multivariate analysis showed that the age at diagnosis and primary site were the independent prognostic factors (Table 3). First, age at diagnosis was related to prognosis in the univariate CSS analysis. Compared with older patients, younger patients were significantly correlated

*Indicates that the Annual Change (APC) is significantly different from zero at the $\alpha = 0.05$ level.
Final Selected Model: 1 Joinpoint.

Figure 1 The incidence of extragonadal choriocarcinoma in male from 1978 to 2013.

Notes: Annual age-adjusted rates of extragonadal choriocarcinoma in male by year (1973–2013). The incidence is presented as the number of patients per 100,000 age-adjusted for the 2000 US standard population.

Table 1 Demographics and clinical characteristics

Characteristic	N	Percentage
Sample size	197	100.0%
Age groups, years		
0–9	6	3.0%
10–19	34	17.3%
20–29	55	27.9%
30–39	36	18.3%
40–49	25	12.7%
50–59	16	8.1%
60–69	18	9.1%
70–79	5	2.5%
80+	2	1.0%
Year of diagnosis		
1973–1982	26	13.2%
1983–1992	35	17.8%
1993–2002	54	27.4%
2003–2013	82	41.6%
Race		
White	158	80.2%
Black/African American	17	8.6%
Other	22	11.2%
Marital status		
Married	79	40.1%
Others	118	59.9%
Grade		
Well differentiated	0	0.0%
Moderately differentiated	1	0.5%
Poorly differentiated	18	9.1%
Undifferentiated	8	4.1%
Unknown	170	86.3%
Location		
Mediastinum	67	34.0%
Retroperitoneum	27	13.7%
Brain (nonpineal)	11	5.6%
Brain (pineal)	7	3.6%
Gastrointestinal	10	5.1%
Bronchus/Lung	6	3.0%
Other	8	4.1%
Unknown	61	31.0%
Histopathology		
Choriocarcinoma, NOS	154	78.2%
Choriocarcinoma combined with other germ cell elements	43	21.8%
Stage		
Localized	4	2.0%
Regional	3	1.5%
Distant	13	6.6%
Unknown	177	89.8%

with a favorable prognosis of survival. The median survival time (Figure 2) was 186 months for the 0- to 19-year-old patients; 13 months in the 20- to 49-year-old patients; and only 4 months in patients aged 50+ years. The multivariate analysis showed that age at diagnosis was an independent prognostic factor. In addition, the brain as the primary site

was related to a favorable prognosis in both univariate and multivariate analyses. The median survival time was 193 months for brain tumors and 12 months for mediastinum tumors.

The variables of diagnosis year and marital status were related to prognosis in our univariate analysis but were not identified as independent prognostic factors in our multivariate analysis. For year of diagnosis, the survival rate tended to increase along decades, and the median survival times were 5, 10, 13 and 20 months in 1973–1982, 1983–1992, 1993–2002 and 2003–2013, respectively. For marital status, we found married patients were related to an unfavorable prognosis in the univariate analysis, but the multivariate analysis excluded it as an independent prognostic factor. To elucidate the reason, we compared the age at diagnosis in married patients with the other marital categories using the *t*-test. The results showed a significantly younger age at diagnosis in married patients than the other marital categories (28.0 ± 16.5 years vs 44.9 ± 15.0 years, $P=0.000$).

Other variables, such as ethnicity and therapeutic treatment (ie, surgery vs beam radiation), were not prognostic factors in the multivariate analysis. First, ethnicity was not correlated to prognosis, despite a worse prognosis for African-American patients when compared with European-American patients or others. Second, surgery and beam radiation treatments were not correlated to prognosis. In fact, the number of surgeries dropped from 77.4% in 1973–1999 to 51.0% in 2000–2013, $P=0.000$. However, the percentage of beam radiation cases was similar at 19.4% and 26.0% in the previous and current centuries, respectively ($P=0.270$).

Discussion

In the present study, we took advantage of the large data set from the SEER Program to investigate the incidence and prognostic factors in the largest series of extragonadal choriocarcinoma in males reported to date. The retrospective study showed that the rates of beam radiation and surgery cases were 22.8% and 63.5%, respectively, and the 5-year CSS rate was 35%. The age at diagnosis and primary site were the independent prognostic factors.

Despite the multiple hypotheses of tumor development, choriocarcinoma is a rare neoplasm, and to the best of our knowledge, the incidence of extragonadal choriocarcinoma in males was first reported in a population-based cohort. Most importantly, according to data collected by Jiang et al,^{16,17} gestational choriocarcinoma affected 1–9.2 in 40,000 pregnancies and 1 in 40 hydatidiform moles, and the inci-

Table 2 Treatment characteristics of choriocarcinoma out of testicle in males

Characteristic	Beam radiation				Surgery		
	N	Rate	Chi-square	P	Rate	Chi-square	P
Overall	197	22.8%			63.5%		
Age groups, years			6.211	0.045		2.377	0.305
0–19	40	32.5%			57.5%		
20–49	116	24.1%			62.1%		
50+	41	9.8%			73.2%		
Year of diagnosis			1.108	0.775		35.243	0.000
1973–1982	26	15.4%			100.0%		
1983–1992	35	25.7%			88.6%		
1993–2002	54	22.2%			48.1%		
2003–2013	82	24.4%			51.2%		
Race			6.902	0.032		0.173	0.917
White	158	19.0%			63.9%		
Black/African American	17	35.3%			58.8%		
Other	22	40.9%			63.6%		
Marital status			3.053	0.081		0.752	0.386
Married	79	16.5%			67.1%		
Others	118	27.1%			61.0%		
Primary site			29.075	0.000		28.269	0.000
Mediastinum	67	13.4%			44.8%		
Retroperitoneum	27	18.5%			51.9%		
Brain	18	72.2%			66.7%		
Other	24	16.7%			62.5%		
Unknown	61	23.0%			88.5%		
Histopathology							
Choriocarcinoma, NOS	154	20.8%	1.704	0.192	64.3%	0.212	0.646
Choriocarcinoma combined with other germ cell elements	43	30.2%			60.5%		

dence ratio of gestational choriocarcinoma to nongestational choriocarcinoma was 79:1, with a male-to-female ratio of 13:33 among patients with nongestational choriocarcinoma. Moreover, nongestational choriocarcinoma in males has been reported at variable anatomical sites with the most occurring in the testes. A total of 106 cases of male choriocarcinoma were reviewed between 1995 and 2006 by Yokoi et al, and the testes were the most common primary tumor site accounting for 33% (35/106).¹⁸ However, testicular choriocarcinoma represents only less than 1% of all germ cell tumors.^{2,19} Interestingly, extragonadal germ cell tumors occur more frequently in the Korean population than in western countries, and the authors considered genetic and dietary factors as possible explanations for the difference.²⁰ The extragonadal germ cell tumor rate among males in the USA is 1.82 times higher than that in Europe, and the authors think that miscoding of registries could be a likely explanation.^{8,9} However, choriocarcinoma was not specified in these studies and was merely described in case reports. For example, the primary mediastinal choriocarcinoma was first described by Arendt in 1931, and only 43 subsequent reports were found by 2014.³

Zhu et al's literature review of primary pulmonary choriocarcinoma in males reflected only 29 cases reported by 2016.⁵ In our study, the incidence of extragonadal choriocarcinoma in males estimated by SEER data was 0.022/100,000 people, and the incidence decreased from 1981.

Extragonadal choriocarcinoma occurs more frequently in younger male patients rather than in older male patients, and furthermore, younger age is a prognostic factor. On the one hand, although there are potentially different mechanisms of development between testicular and extragonadal choriocarcinoma, we found a similar age in peak incidence between the two. The highest incidence of testicular cancer in the USA is between 20 and 34 years old, and the majority of new testicular choriocarcinoma cases develop between 25 and 30 years of age.¹⁴ In our study, the peak incidence of extragonadal choriocarcinoma in males was 20–29 years old, and the majority was younger than 50 years. These findings are in agreement with a literature review involving 41 cases of primary mediastinal choriocarcinoma, which is usually diagnosed in young patients aged between 20 and 30 years old.³ However, 26 cases of primary choriocarcinoma

Table 3 Univariate and multivariate survival analyses for evaluating the prognostic factor of choriocarcinoma out of testis in males

Variable	N	Log-rank			Median survival (months, 95% CI)	P	Univariate analysis		Multivariate analysis	
		1-year CSS	3-years CSS	5-years CSS			HR (95% CI)	P	HR (95% CI)	P
Age groups, years										
0–19	40	66%	60%	57%	186 (13.7 to 358.3)	0.000	1.000		1.000	0.019
20–49	116	49%	34%	33%	13 (5.85 to 20.15)	0.030	0.311 (0.172 to 0.561)	0.000	0.384 (0.186 to 0.790)	0.009
50+	41	32%	21%	15%	4 (0.00 to 9.55)	0.000	0.537 (0.350 to 0.824)	0.004	0.558 (0.345 to 0.901)	0.017
Year of diagnosis										
1973–1982	26	34%	21%	21%	5 (0.0 to 10.0)	0.129	1.000		1.000	0.278
1983–1992	35	46%	34%	34%	10 (0.0 to 21.1)	0.144	1.819 (1.083 to 3.054)	0.024	1.706 (0.996 to 2.923)	0.052
1993–2002	54	49%	37%	35%	13 (4.9 to 21.1)	0.086	1.206 (0.727 to 2.001)	0.468	1.152 (0.691 to 1.922)	0.587
2003–2013	82	56%	44%	39%	20 (7.4 to 18.6)	0.036	1.154 (0.735 to 1.813)	0.533	1.132 (0.716 to 1.788)	0.596
Race										
White	158	50%	37%	35%	13 (6.18 to 19.8)	0.803	1.000		1.000	
Black/African American	17	38%	31%	21%	8 (5.1 to 10.9)	0.538	0.950 (0.542 to 1.664)	0.856		
Other	22	51%	39%	39%	15 (0.0 to 31.5)	0.835	1.152 (0.533 to 2.492)	0.719		
Marital status										
Married	79	39%	27%	27%	9 (6.0 to 12.0)	0.034	1.000		1.000	0.514
Others	118	56%	43%	40%	20 (7.4 to 32.6)	0.034	1.449 (1.015 to 2.067)	0.041	1.142 (0.767 to 1.700)	
Primary site										
Mediastinum	67	49%	27%	25%	12 (5.8 to 18.2)	0.008	1.000		1.000	0.176
Retropertitoneum	27	58%	54%	54%	NA	0.074	0.763 (0.506 to 1.150)	0.196	0.925 (0.599 to 1.428)	0.724
Brain	18	82%	82%	73%	193 (178.6 to 207.4)	0.011	0.422 (0.222 to 0.802)	0.008	0.483 (0.250 to 0.933)	0.030
Other	24	44%	44%	44%	5 (0.9 to 9.1)	0.452	0.312 (0.133 to 0.734)	0.008	0.564 (0.215 to 1.479)	0.244
Unknown	61	39%	27%	25%	8 (3.9 to 12.1)	0.175	0.870 (0.468 to 1.618)	0.659	0.721 (0.376 to 1.383)	0.325
Histopathology										
Choriocarcinoma, NOS	154	46%	35%	33%	12 (5.5 to 18.5)	0.228	1.000			
Choriocarcinoma combined with other germ cell elements	43	60%	42%	42%	20 (0.0 to 43.7)	0.228	1.290 (0.841 to 1.979)	0.243		
Beam Radiation										
Yes	45	48%	39%	35%	13 (3.8 to 22.2)	0.745	1.000			
No	152	49%	36%	34%	13 (6.7 to 19.3)	0.745	1.068 (0.708 to 1.613)	0.753		
Surgery										
Yes	125	51%	37%	35%	16 (7.6 to 24.4)	0.954	1.000			
No	72	46%	36%	34%	12 (7.3 to 16.7)	0.954	1.011 (0.699 to 1.462)	0.956		

Abbreviations: CSS, cause-specific survival; N/A, not applicable.

Figure 2 Plots of cause-specific survival (CSS) duration.

Notes: (A) CSS for the cohort of extragonadal choriocarcinoma in male. (B) CSS by age of diagnosis. Patients were separated into three groups by age of diagnosis. Five-year CSS was 57%, 33% and 15% for those diagnosed among 0–19 years, 20–49 years and 50+ years ($P < 0.05$), respectively. (C) CSS by primary site. Selected patients were separated into three groups by the primary site of tumor. Five-year CSS was 25%, 54%, and 71% for patients of mediastinum, retroperitoneum, and brain tumors.

of the bladder and 53 cases of primary gastric choriocarcinoma reported in the literature showed that the majority of patients were diagnosed at 50+ years of age, and Serno et al found that the median age of male primary pulmonary choriocarcinoma was 60 years.^{6,21,22} Therefore, we speculate that choriocarcinoma at midline locations mainly occurs in young patients, while choriocarcinoma of parenchymal organs tends to affect older patients. On the other hand, our data show that patients who are younger than 20 years have a favorable prognosis. Similarly, Jiang et al analyzed 13 cases of male primary choriocarcinoma reported from the medical center and 100 cases from the scientific literature,

and discovered that patients not older than 34 years had significantly longer survival rates.¹⁷ In fact, the International Federation of Gynecology and Obstetrics 2000 prognostic scoring system was widely used to estimate the prognosis for gestational trophoblastic neoplasia, and age is a prognostic factor.²³ A recent study found that age, ethnicity and tumor stage were independent predictors of mortality of gestational choriocarcinoma.²⁴ Therefore, the findings imply that age is a critical prognostic factor for choriocarcinoma.

Taken together, the tumorigenesis and prognosis of younger patients seem different from those of older patients, and these findings indicate that more detailed research should

be undertaken in the context of pathology and molecular genetics.

In our study, the most common sites of extragonadal choriocarcinoma in males were the mediastinum, retroperitoneum and brain, among which the brain is the primary site directly correlated to a favorable prognosis. Interestingly, the incidence in anatomical locations of extragonadal choriocarcinoma was slightly different from the case series. Yokoi et al described the largest series of 106 cases of male choriocarcinoma reported during 1995–2006, and in addition to testes, the mediastinum, pineal body, gastrointestinal tract, lungs and retroperitoneum were the most common sites; similar results were described by Jiang et al in 2014.^{17,18} Publication bias was inevitable because a literature review of previously published case reports formed the majority of data in both studies. However, the present population-based study provides an overall view of the extragonadal choriocarcinoma in males. Additionally, although choriocarcinoma of the brain was correlated to a favorable prognosis compared with that of the mediastinum, it could be fatal in more than half the patients. A previous study that included intracranial choriocarcinoma in men and women found that the 1-year survival rate was 61.2%, and the prognosis of male patients was better than that of females.²⁵ Choriocarcinoma is the rarest and most malignant of primary intracranial germ cell tumors, accounting for ~3%–5% of all intracranial GCTs, and germ cell tumors comprised 3%–11% of all intracranial neoplasms in children and 1% of all primary intracranial neoplasms in adults.^{26,27} The most common sites of intracranial choriocarcinoma are the pineal and suprasellar regions. Characteristic clinical features include tumor hemorrhage, extraneural and cerebrospinal fluid metastasis, and fetal problems of intracranial choriocarcinoma; these features contribute to its poor prognosis.²⁵

The treatment for primary choriocarcinoma has remained unclear without any standard strategies, and no clinical trial has been reported because of the rarity of this disease; therefore, clinicians often provide patients with surgery, chemotherapy and radiotherapy as choices for treatment.²⁸ Surprisingly, our study did not find that beam radiation or surgery could prolong survival, and further analysis showed that neither radiotherapy nor surgery could prolong survival in a subgroup of intracranial tumors. However, a previous literature review based on 66 reported cases in 1975–2004 revealed that surgery, radiotherapy and chemotherapy were independent prognostic factors in primary intracranial choriocarcinoma/germ-cell tumors with high levels of human chorionic gonadotropin (HCG), although the case selection bias and different treat-

ment protocols should not be overlooked.²⁵ We believe that the treatment efficacy can be omitted in our study because of the limited number of cases. Therefore, we conclude that the best management is based on multidisciplinary therapy, and multicenter clinical trials should be encouraged.

The limitations of this current study include the following: 1) the lack of central verification of pathology diagnosis; 2) the unavailability of information of treatment such as chemotherapy and surgical margin in the SEER database, which may be a critical prognostic factor; 3) the lack of information of biomarkers, such as HCG; 4) and the relatively small sample size, which may still not be enough to fully illustrate the incidence, treatment and prognosis of this rare tumor.

Conclusion

The present study suggests that extragonadal choriocarcinoma in males is a rare malignancy with a poor prognosis. However, a young age at diagnosis and the brain as the primary tumor site were the independent prognostic factors.

Acknowledgments

This work was not supported by any organization. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Schmoll HJ. Extragonadal germ cell tumors. *Ann Oncol.* 2002;13(Suppl 4):265–272.
2. Cheng L, Lyu B, Roth LM. Perspectives on testicular germ cell neoplasms. *Hum Pathol.* 2017;59:10–25.
3. Zhang S, Gao H, Wang XA, et al. Primary choriocarcinoma in mediastinum with multiple lung metastases in a male patient: a case report and a review of the literature. *Thorac Cancer.* 2014;5(5):463–467.
4. Jiang L, Wu JT, Peng X. Primary choriocarcinoma of the colon: a case report and review of the literature. *World J Surg Oncol.* 2013;11:23.
5. Zhu R, Jia C, Yan J, Luo Y, Huo Z. Primary pulmonary choriocarcinoma in a male that was successfully diagnosed and treated: A case report and review of the literature. *Medicine.* 2016;95(52):e5693.
6. Monn MF, Jaqua KR, Bihle R, Cheng L. Primary Choriocarcinoma of the Bladder: A Case Report and Review of Literature. *Clin Genitourin Cancer.* 2017;15(2):188–191.
7. Zhu Y, Liu M, Li J, et al. Breast carcinoma with choriocarcinomatous features: a case report and review of the literature. *World J Surg Oncol.* 2014;12:239.

8. Stang A, Trabert B, Wentzensen N, et al. Burden of extragonadal germ cell tumours in Europe and the United States. *Eur J Cancer*. 2012;48(7):1116–1117.
9. Trama A, Mallone S, Nicolai N, et al. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. 2012;48(2):159–169.
10. Ikura Y, Inoue T, Tsukuda H, Yamamoto T, Ueda M, Kobayashi Y. Primary choriocarcinoma and human chorionic gonadotrophin-producing giant cell carcinoma of the lung: are they independent entities? *Histopathology*. 2000;36(1):17–25.
11. Wang L, Yamaguchi S, Burstein MD, et al. Novel somatic and germline mutations in intracranial germ cell tumours. *Nature*. 2014;511(7508):241–245.
12. Cheung AN, Zhang HJ, Xue WC, Siu MK. Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. *Future Oncol*. 2009;5(2):217–231.
13. Stang A, Trabert B, Wentzensen N, et al. Gonadal and extragonadal germ cell tumours in the United States, 1973–2007. *Int J Androl*. 2012;35(4):616–625.
14. Reilley MJ, Pagliaro LC. Testicular choriocarcinoma: a rare variant that requires a unique treatment approach. *Curr Oncol Rep*. 2015;17(2):2.
15. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med*. 2000;19(3):335–351.
16. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. *Am J Obstet Gynecol*. 2010;203(6):531–539.
17. Jiang F, Xiang Y, Feng FZ, Ren T, Cui ZM, Wan XR. Clinical analysis of 13 males with primary choriocarcinoma and review of the literature. *Onco Targets Ther*. 2014;7:1135–1141.
18. Yokoi K, Tanaka N, Furukawa K, et al. Male choriocarcinoma with metastasis to the jejunum: a case report and review of the literature. *J Nippon Med Sch*. 2008;75(2):116–121.
19. Humphrey PA. Choriocarcinoma of the testis. *J Urol*. 2014;192(3):934–935.
20. Park DS, Chung MK, Chung JI, et al. Histologic type, staging, and distribution of germ cell tumors in Korean adults. *Urol Oncol*. 2008;26(6):590–594.
21. Kobayashi A, Hasebe T, Endo Y, et al. Primary gastric choriocarcinoma: two case reports and a pooled analysis of 53 cases. *Gastric Cancer*. 2005;8(3):178–185.
22. Serno J, Zeppernick F, Jäkel J, et al. Primary pulmonary choriocarcinoma: case report and review of the literature. *Gynecol Obstet Invest*. 2012;74(2):171–176.
23. Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. *Int J Gynaecol Obstet*. 2003;83 Suppl 1(Suppl 1):175–177.
24. Tarney CM, Tian C, Craig ER, et al. Relative effects of age, race, and stage on mortality in gestational choriocarcinoma. *Int J Gynecol Cancer*. 2018;28(2):338–345.
25. Shinoda J, Sakai N, Yano H, Hattori T, Ohkuma A, Sakaguchi H. Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ-cell tumors with high levels of HCG. *J Neurooncol*. 2004;66(1-2):225–240.
26. Kyritsis AP. Management of primary intracranial germ cell tumors. *J Neurooncol*. 2010;96(2):143–149.
27. Hoffman HJ, Otsubo H, Hendrick EB, et al. Intracranial germ-cell tumors in children. *J Neurosurg*. 1991;74(4):545–551.
28. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. *Eur Urol*. 2008;53(3):478–496.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.